TP ICAP MIDCAP analyst reiterated a Buy rating on Esprinet Spa on September 11 and set a price target of €6.20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TP ICAP (Europe) S.A. has given its Buy rating due to a combination of factors including Esprinet Spa’s strong financial performance and strategic positioning. The company reported a 4% year-over-year increase in revenues for the first half of 2025, reaching €1,931 million, which confirms the anticipated rebound and the effectiveness of its strategic repositioning efforts. The sales mix has shifted towards higher value-added segments, such as V-Valley and Zeliatech, which now account for 28% of revenues, up from 25% in 2024.
Additionally, Esprinet’s adjusted EBITDA margin showed a slight improvement, and the results exceeded initial forecasts, reinforcing expectations for a balanced EBITDA contribution throughout the year. The company’s net income also saw a 5% increase despite some cost pressures. The positive outlook is further supported by the structural growth in Solutions and Green Tech, as well as favorable trends in the hardware cycle, which are expected to drive stronger contributions in the second half of the year, particularly in the fourth quarter. These factors, combined with a target price of €6.2, underpin the Buy recommendation.
In another report released on September 13, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a €6.50 price target.
0NFS’s price has also changed moderately for the past six months – from EUR4.579 to EUR5.150, which is a 12.47% increase.